Develops PEDMARK, a formulation of sodium thiosulfate. Focuses on preventing platinum-induced ototoxicity in pediatric cancer patients. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
Sales run at $44.6M a year. A small number, but proof the product has real buyers.
There is $36.7M in the vault; even if every debt were paid off, $36.7M would remain.
Over the last 12 months, company executives reported 84 buys and 40 sells. Management buying with its own money is usually read as a good sign.
A loss of $9.7M against $44.6M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 34/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 48/100.
On our five-subject report card, FENC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FENC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.